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Abstract
Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival rate of less than 4% and desperately needs
novel effective therapeutics. Integrin v6 has been linked with poor prognosis in cancer but its potential as
a target in PDAC remains unclear. We report that transcriptional expression analysis revealed that high levels of
6 mRNA correlated strongly with significantly poorer survival (n= 491 cases, p= 3.17 × 10−8). In two separate
cohorts, we showed that over 80% of PDACs expressed v6 protein and that paired metastases retained v6
expression. In vitro, integrin v6 promoted PDAC cell growth, survival, migration, and invasion. Treatment of
both v6-positive human PDAC xenografts and transgenic mice bearing v6-positive PDAC with the v6
blocking antibody 264RAD, combined with gemcitabine, significantly reduced tumour growth (p< 0.0001) and
increased survival (log-rank test, p< 0.05). Antibody therapy was associated with suppression of tumour cell
activity (suppression of pErk growth signals, increased apoptosis seen as activated caspase-3) and suppression
of the pro-tumourigenic microenvironment (suppression of TGF signalling, fewer SMA-positive myofibroblasts,
decreased blood vessel density). These data show that v6 promotes PDAC growth through both tumour cell and
tumour microenvironment mechanisms and represents a valuable target for PDAC therapy.
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the fifth
leading cause of cancer-related death with a 5-year
survival rate of less than 4% [1] largely due to the
asymptomatic nature and late-stage presentation of the
disease. While new chemotherapy regimens, such as
FOLFIRINOX (fluorouracil, leucovorin, irinotecan,
and oxaliplatin) and gemcitabine with nab-paclitaxel
(nanoparticle albumin-bound paclitaxel), have provided
significant but incremental increases in overall sur-
vival (increasing to 11.1 and 8.5 months, respectively)
compared with standard gemcitabine chemotherapy
(6.7 months for gemcitabine alone [2,3]), the need
to identify more effective therapeutic interventions
remains paramount.
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
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In a small (n= 34) early study [4] it was noted that
the integrin αvβ6 was expressed by PDAC. Integrins
regulate cellular proliferation, adhesion, migration,
and invasion, and their deregulated expression and
signalling can promote cancer progression [5]. Inte-
grins constitute a superfamily of 24 heterodimeric
cell-surface receptors, composed of α and β subunits,
which modulate cell behaviour through bi-directional
signalling between the intracellular and extracellular
compartments [6]. In most normal tissues, αvβ6 expres-
sion is weak or absent, but is up-regulated de novo
by cells undergoing tissue remodelling, including in
carcinogenesis [7]. Moreover, the epithelial-specific
integrin αvβ6 previously has been described as a poor
prognostic marker in multiple cancers [8–11]. How-
ever, a report by Hezel et al [12] showed that antibody
inhibition of αvβ6 in a transgenic PDAC mouse model
(Ptf1-Cre;LSL-RasG12D/+;p53fl/+) seemed to promote
PDAC progression, raising doubts as to its potential as
a therapeutic target. As studies in many other cancers
[8–11] suggested that αvβ6 promoted cancer, and as
novel pancreatic cancer therapies are needed desper-
ately, we have examined the role of αvβ6 clinically,
functionally, and therapeutically in PDAC and conclude
that it should be pursued as a promising target for PDAC
therapy.
Materials and methods
Clinical samples and mRNA expression data
The human tissues used in this study were obtained
under ethical permissions local to the source of mate-
rials. All clinical data were analysed according to
REMARK guidelines [13]. A total of 265 PDAC clini-
cal samples, as two separate tissue microarray (TMA)
slide sets, were provided by The University of Verona,
Italy, and The Beatson Institute, Scotland, UK. Matched
primary and metastatic PDAC samples were supplied
by the Rapid Autopsy Programme, The University of
Nebraska. Eight individual cohorts of mRNA expres-
sion data, totalling 491 patients, were collected from the
Barts Cancer Institute Pancreatic Expression Database,
ICGC PDAC cohort (Biankin), University of Glasgow
(Glasgow), TCGA PDAC cohort (PAAD), as well as
previously published datasets [14–17].
Cell lines and antibodies
KRas-mutant CFPac1, Panc04.03, and Panc1 human
pancreatic cancer cell lines and the human pancreatic
stellate cell line (PS1 [18]) were grown as adherent
monolayers. Cells were grown in a 100% humidified
atmosphere of 8% (volume/volume) of carbon dioxide
(CO2)/air. Cell lines were tested routinely for, and found
free of,Mycoplasma. All cancer cell lines were grown in
Roswell Park Memorial Institute (RPMI)-1640 medium
or Dulbecco’s modified Eagle’s media (DMEM) (PAA
Laboratories, Fisher Scientific UK, Loughborough, UK)
supplemented with 10% foetal calf serum (FCS)
(Biosera, Labtech International, East Sussex, UK) and
glutamine (Sigma-Aldrich, Dorset, UK; 4 mM final
concentration). Human pancreatic stellate (PS1) cells
were grown in a 1:1 mixture of DMEM (E15-843; PAA
Laboratories) and Ham’s F12 (E15-817; PAA Labora-
tories) supplemented with 10% FCS, glutamine (4 mM
final concentration), and 1 μg/ml puromycin (P9620;
Sigma), as a selection agent. The genetic identity of
all human lines was confirmed by STR profiling (LGC
Standards, Teddington, Middlesex, UK).
All clinical samples were labelled with mAb 6.2G2
(anti-β6; a gift from Biogen Idec, Boston, MA, USA)
as previously described [8]. The αvβ6-blocking mouse
antibody 10D5 (MAB2077Z; Sigma-Aldrich) was
purchased and the rat mAb 53A.2 was created by
JFM at Barts Cancer Institute, London. Antibody
264RAD (αvβ6-blocking with some αvβ8-blocking
activity [19]) and IgG control for pre-clinical stud-
ies were supplied by Oncology iMED, AstraZeneca,
Cambridge, UK.
Flow cytometry and FACS
Flow cytometry was performed as previously described
[8]. Briefly, 2 × 105 cells were incubated with 10 μg/ml
of primary antibody in suspension and incubated on
ice for 45min. Controls included unstained cells and
class-matched IgG primary antibodies. The appropriate
secondary AlexaFLUOR (Molecular Probes, Thermo
Fisher, Loughborough, UK) antibodies were added
at 1:250 and incubated for 30min at 4∘C. For flow
cytometry, 10 000 events were acquired by flow cytom-
etry on a FACS Calibur cytometer with Cell Quest
Pro software version 4.0.2 (BD Biosciences, San José,
CA, USA).
In vitro cell proliferation assays
The optimised number of cells (3000–5000 depend-
ing on cell line) were seeded per well, in quadrupli-
cate wells, of 96-well plates and the following day,
αvβ6 function blocking antibodies or control antibody
were added at 0, 0.2, 1, 5, and 10 μg/ml final con-
centration. After 4 days at 37∘C, fresh antibody was
added to the cells at the same concentration and left
until day 7. On day 7, the medium was replaced with
100 μl of MTT reagent (M5655; Sigma-Aldrich) and
generation of formazan product was quantified accord-
ing to themanufacturer’s instructions. Experiments were
conducted with four replicates and repeated at least
three times.
Transwell® migration and invasion assays
For Transwell® assays, 5 × 104 cells were seeded
per well post-treatment into 6.5 mm diameter, 8 μm
pore-size Transwells® (Corning BV, Thermo Fisher).
For migration assays, the underside of the wells was
coated with fibronectin (Sigma-Aldrich) at 10 μg/ml
or TGFβ1 LAP (Sigma-Aldrich) at 1 μg/ml final
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concentration. For invasion assays, the upper surface
of the wells was coated with 70 μl of BD Matrigel
Basement Membrane matrix (Matrigel™; BD Bio-
sciences):media (1:2 ratio). After 16 h (migration) or
72 h (invasion), cells that had migrated/invaded were
trypsin/EDTA harvested and counted using an auto-
mated cell counter CASY (Scharfe Systems, Midland,
Ontario, Canada) as published previously [20].
Immunohistochemistry
Harvested tumours from mice were formalin-fixed
and processed to paraffin wax. Sections were cut at
5 μm thickness, dewaxed, and endogenous peroxi-
dases were blocked with a 0.45% solution of H2O2 in
methanol for 15min. Antibodies to Ki67 (ab92742;
Abcam, Cambridge, UK; 1:200 final dilution), cleaved
caspase-3 (9664S; Cell Signaling Technology, London,
UK; 1:100 final dilution), phospho-ERK (4376S; Cell
Signaling Technology; 1:100 final dilution), endo-
mucin (sc-65495; Santa Cruz Biotechnology, Dallas,
TX, USA; 1:200 final dilution), cytokeratin (ZO622;
Dako, Agilent Technologies, Stockport, UK; 1:500 final
dilution), α-SMA (MO851; Dako; 1:300 final dilu-
tion), phospho-Smad3 (ab52903; Abcam; 1:100 final
dilution), and Smad4 (sc-7966; Santa Cruz Biotechnol-
ogy; 1:300 final dilution) were used to immunostain
tumours using a standard avidin–biotin complex
technique (Vectastain Elite ABC Kit; Vector Labora-
tories, Peterborough, UK). Picro-Sirius red (CI 35782,
Sigma-Aldrich) was used to assess collagen deposi-
tion in tumours. Slides were scanned (Pannoramic
Digital Slide Scanner, 3DHISTECH Ltd, Budapest,
Hungary) and tumour staining was analysed on the
Pannoramic Viewer software (version 1.15.2; 3DHIS-
TECH Ltd) using the NuclearQuant module for Ki67,
Smad4, and pErk, and the DensitoQuant module for
cleaved caspase-3, cytokeratin, and phospho-Smad3.
The number of endomucin-positive blood vessels was
counted using the Ariol ‘Angiosight’ Image Analysis
module (Ariol SL-8; Leica Microsystems, Wetzlar, Ger-
many), and NIH ImageJ freeware (https://imagej.nih
.gov/ij/download.html) was used to quantify collagen
deposition and α-SMA expression. Three independent
observers performed blind scoring of the multiple cores
for each cancer using the following scoring system:
αvβ6 intensity staining was scored out of 4 (0: absent; 1:
background staining; 2: weak; 3: moderate; 4: strong);
and the percentage of epithelial cells staining positively
was scored out of 4 (1: < 25%; 2: 25–50%; 3: 51–75%;
4: 76–100%), where the combined score gave a score
in the range of 0–8. Median scores were determined
and used for statistical analyses. We noted that the
Beatson TMA stained much more weakly than the
Verona TMA, possibly suggesting some degradation of
the target antigen. Patients with a score greater than or
equal to the median score of 3 were considered positive
for αvβ6; 5 or greater was considered strong and the
remaining patients with a median score of less than 3
were considered negative.
Pre-clinical animal studies
All animal experiments followed UK Home Office
Guidelines determined by the Animals (Scientific
Procedures) Act 1986. For human xenograft model
development, 8-week-old female CD1 nu/nu mice
(Charles River Laboratories, Harlow, Essex, UK) were
inoculated subcutaneously (200 μl in the flank) or
orthotopically (40 μl into the tail of the pancreas) with
either 1 × 106 CFPac1 alone or 1 × 106 CFPac1 in
combination with 2 × 106 PS1 cells in PBS. Ortho-
topic xenograft tumours were harvested 6weeks
post-injection, while subcutaneous tumours were
harvested 4weeks post-injection. For the xenograft
antibody therapy study, 8-week-old female CD1 nu/nu
mice were obtained from Charles River Laboratories,
and 1 × 106 CFPac1 in combination with 2 × 106
PS1 cells were injected subcutaneously. Tumours
were measured with callipers bi-weekly in two direc-
tions, where volume was calculated using the formula
(width2 × length)/2. When tumours reached 100mm3,
mice were randomised to receive 4 weeks of bi-weekly
intraperitoneal injections (200 μl) of either 10 mg/kg
human IgG or 264RAD, gemcitabine (Gemzar) at
100mg/kg, or a combination of 100mg/kg gemc-
itabine and 10 mg/kg 264RAD (n= 9 per treatment).
Transgenic KDC (PdxCre+KRasLSL-G12D/+dusp6−/−;
described in the supplementary material, Figure S3)
mouse studies were performed at the CRUK Beatson
Institute, Glasgow, UK. To recapitulate the clinical
setting, KDC animals showing signs of sickness (tented
stance, palpable tumours) received bi-weekly intraperi-
toneal injections (200 μl) of either 10 mg/kg human
IgG plus 100mg/kg gemcitabine, or 10 mg/kg 264RAD
plus 100mg/kg gemcitabine. Mice were culled when
signs of severe sickness were evident. Mice were
sacrificed before tumours reached Home Office vol-
ume limits, at signs of sickness, or after 6 weeks of
therapy.
Statistical analysis
The mRNA abundance data were pre-processed as
outlined previously [21]. In brief, each cohort was
normalised and pre-processed independently. Pair-wise
differences between antibody-treated versus control
in vitro assays and immunohistochemical analysis of
tumours were tested using Student’s t-test. Treatment
differences between in vivo tumour growth treatments
were tested using a Wald test from a normal linear
mixed model fitted by maximum likelihood [22]. A
proportional hazards model was used to compare in
vivo survival, with a log-rank (score) tested for an
overall difference and a Wald test between groups.
Analysis was performed in the statistical software
Prism GraphPad (Version 5.0b; GraphPad Software,
San Diego, CA, USA) and R (R Development Core
Team, 2010 2.15.1) with the nmle package. A P value
equal to or less than 5% was considered statistically
significant.
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019; 249: 332–342
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
The integrin 𝛂v𝛃6 drives pancreatic cancer 335
Results
High β6 mRNA levels correlate with poor overall
survival in PDAC
Eight independent cohorts of PDAC gene expres-
sion datasets, totalling 491 PDAC cases, were each
dichotomised into high (top 25%; red line, Figure 1)
and low (bottom 75%; black line, Figure 1) expressers
based on ITGB6 mRNA expression levels (mRNA
abundance for each cohort is recorded in the supple-
mentary material, Table S1). Combined data show that
with high expressers of ITGB6 (red line; n= 125), there
was a significantly lower overall survival compared
with weak expressers of ITGB6 (black line; n= 366)
[hazard ratio (HR): 2.07; 95% confidence interval (CI):
1.59–2.69; log-rank test: p= 3.17 × 10−8] (Figure 1,
lower histogram).
αvβ6 protein is expressed by most PDACs and is
retained by metastases
Two separate cohorts of PDAC samples were analysed
independently for expression of αvβ6. The Beatson
cohort had 118 PDAC cases and 12 normal pancreata,
whereas the Verona dataset had 147 patients and 20
normal pancreata. Examples of typical staining are
shown in Figure 2A. Expression of αvβ6 was restricted
specifically to epithelial cells as observed previously
[7,8]. Normal pancreas samples were mostly negative
for αvβ6, though occasionally some duct cells expressed
αvβ6 weakly. Expression of αvβ6 was detected in 98%
(median score≥ 3) of Verona samples and 83% of Beat-
son samples, although staining intensity was uniformly
weaker on the Beatson TMA and thus staining may
be an underestimate. Using a median score of ≥ 5 to
represent strong staining (as shown on the PanIN and
PDAC in Figure 2A), 84% of Verona PDAC samples
expressed αvβ6 strongly. We then examined six PDAC
patients for whom we had primary tumour tissue and
their matched metastatic tumours from lung, colon or
liver; all the primary tumours expressed αvβ6 strongly
and all metastases were also αvβ6-positive, 70% retain-
ing similarly strong expression to that of the matched
primary (Figure 2B and Table 1).
Blockade of αvβ6 reduces proliferation, migration,
and invasion of αvβ6-positive pancreatic cancer
cells in vitro
Integrin αvβ6 was expressed on seven out of nine
pancreatic tumour cell lines, as determined by flow
cytometry (see supplementary material, Table S2).
The αvβ6-blocking antibodies 53A.2 (Figure 3A)
and 264RAD (Figure 3B) similarly and significantly
reduced the proliferation of αvβ6-positive, but not
αvβ6-negative, PDAC cancer cells. Both antibod-
ies also reduced the migration of αvβ6-positive
Panc04.03 and CFPac1 pancreatic cancer cells
towards their ligand LAP (Figure 2C,D). 10D5
(αvβ6-blocking) and 264RAD also reduced the
invasion of these αvβ6-positive cells through
Matrigel™-coated Transwells® (Figure 3E,F), com-
pared with control-treated cells and αvβ6-negative
Panc1 cells. Thus, αvβ6 promotes PDAC cancer cell
growth, migration, and invasion.
264RAD antibody therapy reduces the growth
of pancreatic human xenograft tumours
CFPac1 cells were injected alone or in combination
with a human pancreatic stellate cell (PSC) line (PS1)
orthotopically or subcutaneously. The presence of PSCs
reduced the number and density of endomucin-positive
blood vessels and increased collagen deposition com-
pared with CFPac1 cells growing alone (see supple-
mentary material, Figure S1). Since both the subcuta-
neous and the orthotopic tumours with PSCs developed
similar hypovascular and desmoplastic stroma seen in
human pancreatic cancer [23,24], we used the more
easily tractable subcutaneous xenograft model for the
αvβ6-blocking 264RAD [19] antibody therapy studies
in vivo.
Treatment of mice bearing 100mm3 CFPac1/PS1
subcutaneous tumours with 264RAD demonstrated
significantly reduced tumour growth, compared with
isotype control (p ≤ 0.0001) (Figure 4A). Treatment
of tumours with gemcitabine alone also significantly
reduced tumour growth compared with isotype con-
trol (p ≤ 0.0001), or when compared with 264RAD
monotherapy (p = 0.012). However, the combination of
264RAD with gemcitabine demonstrated the greatest
reduction in tumour volume of all mice during treatment,
compared with isotype control (p ≤ 0.0001), or com-
pared with gemcitabine alone (p = 0.028) (Figure 4A
and see supplementary material, Figure S2). In fact,
the tumours in three mice treated with 264RAD plus
gemcitabine vanished completely (see supplementary
material, Figure S2). No toxicity (loss of weight, change
in appearance or behaviour) was observed in any mice
during any treatment (data not shown).
To determine the molecular mechanisms associated
with 264RAD-induced tumour reduction, immuno-
chemistry demonstrated a significant down-regulation
of proliferation (Ki67) and growth signalling (phospho-
rylated Erk), and a significant up-regulation of apoptosis
(cleaved caspase-3; Figure 4B) in the 264RAD-treated
tumours compared with control-treated tumours
(p ≤ 0.0001) (Figure 4C).
Therapy with the αvβ6-blocking 264RAD antibody
significantly improves survival
in immunocompetent transgenic mice bearing
αvβ6-expressing PDAC tumours
We sought to determine the effect of 264RAD
antibody therapy on PDAC using immuno-
competent transgenic mice. The pathological
development of PDAC in well-established KPC
(PdxCre+KRasLSL-G12D/+p53LSL-R172H/+) mice closely
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Figure 1. Expression of αvβ6 at the mRNA level in human PDAC. Kaplan–Meier survival curves of PDAC patients based on integrin β6 gene
(ITGB6) expression at the mRNA level from eight cohorts: Barts Cancer Institute (BCI) pancreatic expression database, IGCG PDAC cohort
(Biankin), University of Glasgow (Glasgow), TCGA PDAC cohort (PAAD), as well as previously published datasets (Collisson, Stratford, Winter,
and Zhang [14–17]). The red line indicates the upper quartile of ITGB6-positive patients and the black line indicates ITGB6-weakly positive
or -negative patients. The lower histogram shows the combined Kaplan–Meier survival analysis of the total of 491 PDAC patients based
on integrin β6 mRNA (ITGB6) expression. Again, the red line indicates the upper quartile of ITGB6-positive patients (n= 125) and the black
line ITGB6-weakly positive or -negative patients (n= 366). Hazard ratio (HR)= 2.07 (95% CI 1.59–2.69); log-rank test p= 3.17 × 10−8.
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019; 249: 332–342
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Figure 2. Expression of αvβ6 protein in human PDAC. FFPE PDAC tissues were labelled with mAb 6.2G2 to assess αvβ6 expression. (A)
Representative images of human normal pancreas, PanIN, and invasive PDAC tumour tissue stained for αvβ6 expression are shown. Scale
bar= 100 μm. (B) Representative staining for αvβ6 expression in a primary tumour and paired metastases from a single patient is shown,
with an enlarged inset for improved clarity. Scale bar= 50 μm.
Table 1. Expression of αvβ6 in primary PDAC and matched
metastases
Tumour site Cases
Strong
v6
expression
Moderate, weak,
nil v6
expression
Primary Pancreas 6 6 (100%) 0 (0%)
Metastases Liver 6 3 (50%) 3 (50%)
Lung 2 2 (100%) 0 (0%)
Colon 5 4 (80%) 1 (20%)
Sections of primary PDAC tumours and patient-matched secondary tumours were
collected from six patients (generous gift from the Rapid Autopsy Programme,
The University of Nebraska) and stained for expression of αvβ6 using immuno-
histochemistry. All primary tumours expressed αvβ6 strongly (median score≥ 5)
and all metastases retained αvβ6 expression, 70% retaining strong expression.
matches the progression of human disease [25]. How-
ever, unlike in humans where αvβ6 is expressed on most
human PDACs (see above), integrin αvβ6 was detected
only in PanIN lesions but not in the PDAC primary
tumours of KPC mice (data not shown). Therefore, we
examined a new transgenic pancreatic cancer model
called KDC (PdxCre+KRasLSL-G12D/+dusp6−/−), whose
mice possess the same activating mutation in KRas as
KPC mice together with deletion of the dual-specificity
phosphatase 6 (dusp6) targeted to the pancreas. These
mice develop PanIN lesions which progress to invasive,
metastatic PDAC between 3 and 10 months of age (see
supplementary material, Figure S3). Similar to human
disease, we discovered that KDC mice demonstrated
a striking expression of αvβ6 in PanINs and primary
tumours (Figure 5A). Mirroring human therapy, in
which therapeutic intervention is usually administered
in late-stage disease, KDC mice with palpable pan-
creatic tumours and displaying visible symptoms of
sickness were treated with gemcitabine in combina-
tion with 264RAD or isotype control antibody. The
264RAD-treated mice showed significantly increased
overall survival in comparison with isotype control
treated animals (log-rank test p = 0.028; HR: 4.92; 95%
CI: 1.04–23.28) (Figure 5B). Immunohistochemistry
revealed that 264RAD treatment of PDAC-bearing
KDC mice significantly reduced tumour cell prolifer-
ation (Ki67), tumour growth signalling (pErk), blood
vessel density (endomucin), and TGFβ signalling
(nuclear Smad4), and showed a trend towards reduced
phosphorylated Smad3, αSMA, and collagen deposition
(Figure 5C,D).
Discussion
Cytotoxic pharmaceuticals remain the principal tool for
therapy of PDAC and while there have been promising
developments that offer incremental increases in sur-
vival of additional months [2,3] patients still need vastly
improved therapies if we are to significantly improve
upon the 5-year survival rate of less than 4%. Our data
suggest that combining blockade of integrin αvβ6 with
cytotoxic therapy could significantly help to achieve
that goal.
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Figure 3. Antibody blockade of αvβ6 inhibits proliferation, migration, and invasion of PDAC cell lines. Proliferation of Panc04.03, CFPac1,
and Panc1 cells treated with varying concentrations of αvβ6 function-blocking antibodies, (A) 53A.2 (purple) or (B) 264RAD (red), versus
IgG control (black). Two-way ANOVA (Bonferroni’s correction), *p< 0.05; **p< 0.01; ***p< 0.001. Migration of PDAC cells towards the
latency-associated peptide (LAP) of TGFβ, compared with BSA control, following incubation with (C) 53A.2 (purple) or (D) 264RAD (red)
versus IgG control (black) used at the same concentration. Data show the mean± SEM of three independent experiments performed in
quadruplicates. Two-way ANOVA, **p< 0.005; ***p< 0.001. Invasion of PDAC cells through Matrigel™ following treatment with (E) 10D5
(purple) or (F) 264RAD (red) compared with IgG control antibody (black) used at the same concentration. The number of invaded cells
was counted after 72 h. Data show the mean± SEM of three independent experiments performed in triplicate. Student’s t-test, *p< 0.05;
****p< 0.0001.
We, and others, have reported that high expression
of the pro-invasive integrin αvβ6 correlates with poor
overall survival from cancer [8–11]. Thus, when Sipos
et al reported [4] that all of their 34 PDAC cases anal-
ysed expressed αvβ6, it was reasonable to assume that
this integrin would also promote this disease. However,
a robust study from Hezel et al [12] suggested that
αvβ6 was a tumour suppressor in PDAC, probably
through local activation of TGFβ. It is well estab-
lished that TGFβ can be both tumour-suppressive and
tumour-promoting (reviewed in refs 26 and 27). Amajor
mechanism by which TGFβ suppresses normal epithe-
lial growth is through activation of cyclin-dependent
kinases p21 and p15. However, carcinoma cells often
develop mutations that make them refractory to this
growth suppression and allowing them to respond
directly to the ability of TGFβ to promote invasion
or indirectly by TGFβ-dependent generation of a
tumour-permissive microenvironment [26]. Hezel et al
used the Ptf1-Cre;LSL-RasG12D/+;p53fl/+ mice that
develop PDAC relatively early, at 9–10 weeks [12].
They reported that antibody blockade of αvβ6 (or TGFβ)
promoted early development of PanINs and progression
to PDAC, but had no effect on the tumour microenviron-
ment, and that these observations correlated with TGFβ
signalling and αvβ6 expression. Thus, their data are
consistent with the conclusion that the transformed pan-
creatic ductal cells in Ptf1-Cre;LSL-RasG12D/+;p53fl/+
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019; 249: 332–342
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Figure 4. 264RAD therapy in the CFPac1/PS1 subcutaneous human
xenograft mouse model of pancreatic cancer. (A) A total of
0.5 × 106 CFPac1 cells and 1 × 106 PS1 cells were co-injected sub-
cutaneously into female CD1nu/nu mice. When tumours reached
approximately 100mm3, mice were entered into four different
treatment arms: IgG isotype control antibody (10 mg/kg); 264RAD
(10 mg/kg); gemcitabine (100mg/kg); or 264RAD (10 mg/kg) and
gemcitabine (100mg/kg) (n= 9 per group). Animals were treated
bi-weekly for 4 weeks. Data were analysed using a linear mixed
model fitted to log volume [22]; *p< 0.05; ***p< 0.0001. (B)
Representative images and (C) quantification of IgG-treated and
264RAD-treated tumours stained for Ki67, cleaved caspase-3, and
phosphorylated ERK (pERK). Student’s t-test, ***p< 0.0001. Scale
bar= 50 μm.
mice retain the TGFβ-dependent growth-suppressive
signalling pathways even when they have developed into
PanINs and PDAC. Another mechanism that may be rel-
evant was reported by David et al [28] who showed that
PDAC cells that retained functional SMAD4 signalling
underwent TGFβ-dependent EMT that transitioned to
apoptosis driven by the repurposing of the transcrip-
tion factor Sox4. Thus, in this situation, inhibition
of αvβ6-dependent activation of TGFβ would reduce
apoptosis and enhance PDAC survival. However, the
number of PDAC tumours retaining TGFβ-dependent
SMAD signalling is likely to be a smaller fraction of
humans with PDAC, since most human PDACs have
genetic dysfunction in TGFβ signalling [26,27].
Analysis of the expression of ITGB6 mRNA on eight
separate cohorts showed that high (top 25% quartile)
expression, in general, correlated with poorer survival.
When the data from all 491 PDAC cases were analysed,
the high expression group was associated with signifi-
cantly poorer survival (Figure 1; HR: 2.07; log-rank test:
p= 3.17 × 10−8). Thus, there is a clear association link-
ing β6 and survival from PDAC. Our data also showed
that in addition to most PDACs expressing αvβ6 on their
surface, the integrin is retained by metastases, so thera-
pies directed to this integrin would target both primary
and secondary disease.
To investigate the role of αvβ6 in PDAC experi-
mentally, we examined a panel of PDAC cell lines
and confirmed that seven of nine expressed αvβ6
(see supplementary material, Table S2). When we
grew αvβ6-expressing (Panc0403 and CFPac1) and
αvβ6-negative (Panc1) cell lines in the presence of
two different αvβ6-blocking antibodies (53a2 and
264RAD), we noted that, compared with control IgG,
both αvβ6-blocking antibodies suppressed growth
(Figure 3A,B). This is consistent with the report of
Singh et al [29] that the ITGB6 gene is required for
Ras-oncogene-dependent growth of PDAC cells.We fur-
ther showed that αvβ6 promoted migration and invasion
(Figure 3C–F), confirming that, as has been shown for
other cell types [8,20,30], αvβ6 imparts greater prolif-
erative, migratory, and invasive capacity to PDAC cells.
To establish whether αvβ6 could be an effective thera-
peutic target, we tested two novel PDAC tumour models
that reflect human disease. We generated a xenograft
from combined injection of human PDAC and pan-
creatic stellate cells (CFPac1/PS1) that developed
desmoplastic, hypoangiogenic tumours, mimick-
ing human disease [23]. Treatment with 264RAD,
which blocks αvβ6 function, stopped established
tumours growing and enhanced gemcitabine therapy
(p< 0.0001), even curing 33% of mice in the com-
bination therapy group (see supplementary material,
Figure S3). Mechanistically, the 264RAD antibody
increased apoptosis and blocked pErk growth signals
and tumour cell division (Figure 4C). Thus, just as
we have reported in breast and oral tumours [8,19]
inhibition of αvβ6 with 264RAD could abrogate and
sometimes even eliminate established PDAC tumours.
The human xenograft studies required immunodefi-
cient mice and thus we turned to a new transgenic PDAC
mouse model, KDC (PdxCre+KRasLSL-G12D/+dusp6−/−),
which combines a RasG12D mutation with loss of
dual-specific phosphatase 6 (Dusp6), considered a
potential tumour suppressor in PDAC [31]; in KDC
mice, αvβ6 was expressed in PanINs and PDAC tumours
(Figure 5). Blockade of αvβ6 with 264RAD in com-
bination with gemcitabine significantly (HR: 4.92;
log-rank test p = 0.028) increased survival of KDC
mice (Figure 5). This is in agreement with our human
xenograft study but is in contrast to the report by Hezel
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Figure 5. Treatment of PDAC-bearing KDC mice with 264RAD and immunohistochemical analysis. (A) Representative immunohistochemical
analysis of αvβ6 expression in normal, PanIN, and PDAC from PdxCre+KRasLSL-G12D/+Dusp6−/− (KDC) mice. Normal pancreas shows no αvβ6
on acinar cells and weak staining on some ductal cells. Strong expression of αvβ6 protein was evident in PanIN and PDAC. (B) Kaplan–Meier
survival curve of KDC mice treated with IgG isotype control (10 mg/kg) and gemcitabine (100mg/kg) (grey line; n= 4), or 264RAD (10 mg/kg)
and gemcitabine (100mg/kg) (purple line; n= 8). A significant increase in survival upon treatment with 264RAD is evident. Hazard ratio
(HR)= 4.92 (CI: 1.04–23.28); log-rank p= 0.028. (C) PDAC tumours from KD mice treated with IgG isotype control and gemcitabine or
264RAD and gemcitabine were analysed using immunohistochemistry for markers of tumourigenesis. Representative images of staining for
Ki67, cleaved caspase-3 (C-Casp-3), cytokeratin 19 (CK19), alpha-smooth muscle actin (αSMA), collagen, endomucin Endo), phosphorylated
Smad3 (pSmad3), nuclear Smad4, and phosphorylated Erk (pErk) are displayed. Scale bar= 50 μm. (D) Quantification of staining using image
analysis as described in the Materials and methods section. Data show the mean± SEM of three tissue samples per group. Student’s t-test,
*p= 0.05.
et al that suggested a tumour-suppressive role of αvβ6 in
PDAC [12]. Moreover, immunohistochemistry results
revealed that tumours from KDC mice treated with
264RAD had significantly reduced proliferation (Ki67),
tumour growth signalling (pErk), blood vessel density
(endomucin), and TGFβ signalling (nuclear Smad4),
and showed a trend towards reduced desmoplasia
(reduced αSMA-expressing myofibroblasts and colla-
gen deposition). Thus, antibody blockade of αvβ6 corre-
lated with both direct anti-tumour cell effects (reduced
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Figure 6. Mechanisms by which integrin αvβ6 promotes pancreatic
ductal adenocarcinoma. Our data show that αvβ6 promotes PDAC
by modulating the behaviour of both the cancer cells and the
tumour microenvironment.
pErk, Ki67) and generation of a less tumour-permissive
stroma. Together with reduced migratory and invasive
capacity, these effects combine to suppress PDAC
growth and increase overall survival. Figure 6 shows
our current model of how αvβ6 affects PDAC growth.
Of all cancer conditions, PDAC remains the one that is
most desperate for novel therapeutic strategies. As αvβ6
is expressed by the majority of human PDACs, and as
our clinical, functional, and pre-clinical animal studies
combine to show that this integrin actively promotes this
disease, we must consider αvβ6 as a promising target for
the therapy of PDAC in combination with conventional
therapies.
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